CureZone   Log On   Join

Regorafenib: An Oral Multi-kinase Inhibitor by marykudro ..... Cancer Forum

Date:   10/28/2021 10:14:02 AM ( 17 months ago ago)
Hits:   357

0 of 0 (0%) readers agree with this message.  Hide votes     What is this?

Regorafenib is introduced under the brand name Stivarga. It is mainly an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic RTK. The medical approval of regorafenib includes Metastatic colorectal cancer, Advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma. Regorafenib represents the anti-angiogenic activity because of its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. This drug is being approved with a Boxed Warning alerting patients and health specialists that fatal liver toxicity may occur in recipients treated with regorafenib during clinical studies.


<< Return to the standard message view

fetched in 0.03 sec, referred by